Identification of small molecular weight inhibitors of Src homology 2 domain-containing tyrosine phosphatase 2 (SHP-2) via in silico database screening combined with experimental assay

Journal of Medicinal Chemistry

Volumn 51, Issue 23, 2008, Pages 7396-7404

  Yu, Wen Mei ^a   Guvench, Olgun ^b   MacKerell Jr , Alexander D ^b   Qu, Cheng Kui ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN TYROSINE PHOSPHATASE INHIBITOR; PROTEIN TYROSINE PHOSPHATASE SHP;

AMINO ACID SEQUENCE; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DATA BASE; EMBRYO; ENZYME ACTIVE SITE; ENZYME BINDING; IC 50; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PROTEIN CONFORMATION; SEQUENCE HOMOLOGY;

ANIMALS; BINDING SITES; CELL LINE; CELL PROLIFERATION; COMPUTATIONAL BIOLOGY; COMPUTER-AIDED DESIGN; CRYSTALLOGRAPHY, X-RAY; DATABASES, FACTUAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; MICE; MODELS, MOLECULAR; MOLECULAR STRUCTURE; MOLECULAR WEIGHT; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 57349141440     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm800229d     Document Type: Article

References (42)

1. Neel, B. G.; Gu, H.; Pao, L. The "shp"ing news: SH2 domain-containing tyrosine phosphatases in cell signaling. Trends Biochem. Sci. 2003, 28, 284-293.
2. Tonks, N. K. Protein tyrosine phosphatases: from genes, to function, to disease. Nat. Rev. Mol. Cell Biol. 2006, 7, 833-846.
3. Qu, C. K. Role of the SHP-2 tyrosine phosphatase in cytokine-induced signaling and cellular response. Biochim. Biophys. Acta 2002, 1592, 297-301.
4. Eck, M. J.; Pluskey, S.; Trub, T.; Harrison, S. C.; Shoelson, S. E. Spatial constraints on the recognition of phosphoproteins by the tandem SH2 domains of the phosphatase SH-PTP2. Nature 1996, 379, 277-280.
5. Hof, P.; Pluskey, S.; Dhe-Paganon, S.; Eck, M. J.; Shoelson, S. E. Crystal structure of the tyrosine phosphatase SHP-2. Cell 1998, 92, 441-450.
6. Tartaglia, M.; Mehler, E. L.; Goldberg, R.; Zampino, G.; Brunner, H. G.; Kremer, H.; van der Burgt, I.; Crosby, A. H.; Ion, A.; Jeffery, S.; Kalidas, K.; Patton, M. A.; Kucherlapati, R. S.; Gelb, B. D. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat. Genet. 2001, 29, 465-468.
7. Tartaglia, M.; Niemeyer, C. M.; Fragale, A.; Song, X.; Buechner, J. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat. Genet. 2003, 34, 148-150.
8. Loh, M. L.; Vattikuti, S.; Schubbert, S.; Reynolds, M. G.; Carlson, E.; Jung, A.; Hahlen, K.; Hasle, H.; Licht, J. D.; Gelb, B. D. Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis. Blood 2004, 103, 2325-2331.
9. Bentires-Alj, M.; Paez, J. G.; David, F. S.; Keilhack, H.; Halmos, B.; Naoki, K.; Maris, J. M.; Richardson, A.; Bardelli, A.; Sugarbaker, D. J.; Richards, W. G.; Du, J.; Girard, L.; Minna, J. D.; Loh, M. L.; Fisher, D. E.; Velculescu, V. E.; Vogelstein, B.; Meyerson, M.; Seller, W. R.; Neel, B. G. Activating mutations of the Noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res. 2004, 64, 8816-8820.
10. Araki, T.; Mohi, M. G.; Ismat, F. A.; Bronson, R. T.; Williams, I. R.; Kutok, J. L.; Yang, W.; Pao, L. I.; Gilliland, D. G.; Epstein, J. A.; Neel, B. G. Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation. Nat. Med. 2004, 10, 849-857.
11. Mohi, M. G.; Williams, I. R.; Dearolf, C. R.; Chan, G.; Kutok, J. L.; Cohen, S.; Morgan, K.; Boulton, C.; Shigematsu, H.; Keilhack, H.; Akashi, K.; Gilliland, D. G.; Neel, B. G. Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations. Cancer Cell 2005, 7, 179-191.
12. Chan, R. J.; Leedy, M. B.; Munugalavadla, V.; Voorhorst, C. S.; Li, Y.; Yu, M.; Kapur, R. Human somatic PTPN11 mutations induce hematopoietic-cell hypersensitivity to granulocyte-macrophage colony-stimulating factor. Blood 2005, 105, 3737-3742.
13. Schubbert, S.; Lieuw, K.; Rowe, S. L.; Lee, C. M.; Li, X.; Loh, M. L.; Clapp, D. W.; Shannon, K. M. Functional analysis of leukemia-associated PTPN11 mutations in primary hematopoietic cells. Blood 2005, 106, 311-317.
14. Yu, W. M.; Daino, H.; Chen, J.; Bunting, K. D.; Qu, C. K. Effects of a leukemia-associated gain-of-function mutation of SHP-2 phosphatase on interleukin-3 signaling. J. Biol. Chem. 2006, 281, 5426-5434.
15. Chen, L.; Sung, S. S.; Yip, M. L.; Lawrence, H. R.; Ren, Y.; Guida, W. C.; Sebi, S. M.; Lawrence, N. J.; Wu, J. Discovery of a novel shp2 protein tyrosine phosphatase inhibitor. Mol. Pharmacol. 2006, 70, 562-570.
16. Barford, D.; Neel, B. G. Revealing mechanisms for SH2 domain mediated regulation of the protein tyrosine phosphatase SHP-2. Structure 1998, 6, 249-254.
17. Bernstein, F. C.; Koetzle, T. F.; Williams, G. J.; Meyer, E. F., Jr.; Brice, M. D.; Rodgers, J. R.; Kennard, O.; Shimanouchi, T.; Tasumi, M. The Protein Data Bank. A computer-based archival file for macromolecular structures. Eur. J. Biochem. 1977, 80, 319-324.
18. Word, J. M.; Lovell, S. C.; Richardson, J. S.; Richardson, D. C. Asparagine and glutamine: using hydrogen atom contacts in the choice of side-chain amide orientation. J. Mol. Biol. 1999, 285, 1735-1747.
19. MacKerell, A. D., Jr.; Bashford, D; Bellott, M; Dunbrack, R. L.; Evanseck, J. D.; Field, M. J.; Fischer, S; Gao J; Guo, H; Ha, S; Joseph-McCarthy, D; Kuchnir, L; Kuczera, K; Lau, F. T. K.; Mattos, C; Michnick, S; Ngo, T; Nguyen, D. T.; Prodhom, B; Reiher, W. E.; Roux, B; Schlenkrich, M; Smith, J. C.; Stote, R; Straub, J; Watanabe, M; Wiorkiewicz-Kuczera, J; Yin, D; Karplus, M. All-atom empirical potential for molecular modeling and dynamics studies of proteins. J. Phys. Chem. B 1998, 102, 3586-3616.
20. MacKerell, A. D., Jr,; Feig, M.; Brooks, C. L., III. Extending the treatment of backbone energetics in protein force fields: limitations of gas-phase quantum mechanics in reproducing protein conformational distributions in molecular dynamics simulations. J. Comput. Chem. 2004, 25, 1400-1415.
21. Kuntz, I. D.; Blaney, J. M.; Oatley, S. J.; Langridge, R.; Ferrin, T. E. A geometric approach to macromolecule-ligand interactions. J. Mol. Biol. 1982, 161, 269-288.
22. Kuntz, I. D. Structure-based strategies for drug design and discovery. Science 1992, 257, 1078-1082.
23. Connolly, M. L. Solvent-accessible surfaces of proteins and nucleic acids. Science 1983, 221, 709-713.
24. Ferrin, T. E.; Huang, C. C.; Jarvis, L. E.; Langridge, R. The MIDAS display system. J. Mol. Graphics 1988, 6, 13-27.
25. Yang, J.; Cheng, Z.; Niu, T.; Liang, X.; Zhao, Z. J.; Zhou, G. W. Structural basis for substrate specificity of protein-tyrosine phosphatase SHP-1. J. Biol. Chem. 2000, 275, 4066-4071.
26. Goodford, P. J. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. J. Med. Chem. 1985, 28, 849-857.
27. Pan, Y.; Huang, N.; Cho, S.; MacKerell, A. D., Jr. Consideration of molecular weight during compound selection in virtual target-based database screening. J. Chem. Inf. Comput. Sci. 2003, 43, 267-272.
28. Huang, N.; Nagarsekar, A.; Xia, G.; Hayashi, J.; MacKerell, A. D., Jr. Identification of non-phosphate-containing small molecular weight inhibitors of the tyrosine kinase p56 Lck SH2 domain via in silico screening against the pY + 3 binding site. J. Med. Chem. 2004, 47, 3502-3511.
29. Humphrey, W.; Dalke, A.; Schulten, K. VMD: visual molecular dynamics. J. Mol. Graphics 1996, 14, 33-38, 27-38.
30. Leach, A. R.; Kuntz, I. D. Conformational analysis of flexible ligands in macromolecular receptor sites. J. Comput. Chem. 1992, 13, 730-748.
31. Ewing, T. J. A.; Kuntz, I. D. Critical evaluation of search algorithms used in automated molecular docking. J. Comput. Chem. 1997, 18, 1175-1189.
32. Kelley, L. A.; Gardner, S. P.; Sutcliffe, M. J. An automated approach for clustering an ensemble of NMR-derived protein structures into conformationally related subfamilies. Protein Eng. 1996, 9, 1063-1065.
33. Jarvis, R. A.; Patrick, E. A. Clustering Using a Similarity Measure Based on Shared Near Neighbors. IEEE Trans. Comput. 1973, C22, 1025-1034.
34. Tanimoto, T. T. IBM Internal Report, Nov. 17, 1957.
35. Butina, D. Unsupervised database clustering on daylight's fingerprint and Tanimoto similarity: A fast and automated way to cluster small and large data sets. J. Chem. Inf. Comput. Sci. 1999, 39, 747-750.
36. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery Rev. 2001, 46, 3-26.
37. Yang, J.; Liang, X.; Niu, T.; Meng, W.; Zhao, Z.; Zhou, G. W. Crystal structure of the catalytic domain of protein-tyrosine phosphatase SHP-1. J. Biol. Chem. 1998, 273, 28199-28207.
38. Yang, J.; Liu, L.; He, D.; Song, X.; Liang, X.; Zhao, Z. J.; Zhou, G. W. Crystal structure of human protein-tyrosine phosphatase SHP-1. J. Biol. Chem. 2003, 278, 6516-6520.
39. Imhof, D.; Wavreille, A. S.; May, A.; Zacharias, M.; Tridandapani, S.; Pei, D. Sequence specificity of SHP-1 and SHP-2 Src homology 2 domains. Critical roles of residues beyond the pY + 3 position. J. Biol. Chem. 2006, 281, 20271-20282.
40. Oprea, T. I.; Davis, A. M.; Teague, S. J.; Leeson, P. D. Is there a difference between leads and drugs? A historical perspective. J. Chem. Inf. Comput. Sci. 2001, 41, 1308-1315.
41. Keilhack, H.; David, F. S.; McGregor, M.; Cantley, L. C.; Neel, B. G. Diverse biochemical properties of Shp2 mutants. Implications for disease phenotypes. J. Biol. Chem. 2005, 280, 30984-30993.
42. Yu, W. M.; Hawley, T. S.; Hawley, R. G.; Qu, C. K. Catalytic-dependent and -independent roles of SHP-2 tyrosine phosphatase in interleukin-3 signaling. Oncogene 2003, 22, 5995-6004.